newsfilter
← Latest News
PR Newswire·

Tetra Bio-Pharma's QIXLEEF™ on Track After Type C Meeting with U.S. FDA

The Type C meeting with the FDA provides guidance to strengthen QIXLEEF™ nonclinical and toxicological data package for marketing approval. OTTAWA, ON, March 17, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTC